RxSight, Inc.
Item 1(b) | Address of Issuer’s Principal Executive Offices: |
100 Columbia
Aliso Viejo, California 92656
Item 2 | (a) Name of Person Filing: |
This Schedule 13G is being filed by the following persons (each a “Reporting Person” and, collectively, the “Reporting Persons”):
| i. | H.I.G. BioVentures—Calhoun, LLC, a Delaware limited liability company; |
| ii. | H.I.G.-GPII, Inc., a Delaware Corporation (and, together with H.I.G. BioVentures – Calhoun, LLC, the “H.I.G. Entities”); |
| iii. | Anthony Tamer, a United States Citizen; and |
| iv. | Sami Mnaymneh, a United States Citizen |
During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or other administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgement, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 2 (b) | Address of Principal Business Office or, if none, Residence: |
The principal business address for each of the H.I.G. Entities, Mr. Tamer and Mr. Mnaymneh is 1450 Brickell Avenue, 31st Floor, Miami, FL 33131
H.I.G. BioVentures – Calhoun, LLC is a Delaware limited liability company. H.I.G.-GPII, Inc. is a Delaware corporation. Mr. Tamer and Mr. Mnaymneh are U.S. Citizens.
Item 2 (d) | Title of Class of Securities: |
Common stock, par value $0.001 per share
78349D107
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
Page 6 of 9